Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma.
Ludwig C et al. Blood Cancer J. 2015 Oct 16;5:e359. doi: 10.1038/bcj.2015.85.

Impact of cytogenetic classification on outcomes following early high dose therapy in multiple myeloma.
Kaufman GP et al. Leukemia. 2015 Oct 21. doi: 10.1038/leu.2015.287. [Epub ahead of print].

Insight into human protease activated receptor-1 as anticancer target by molecular modelling.
Hidayat AN et al. SAR QSAR Environ Res. 2015 Oct 26:1-13. [Epub ahead of print].

Control of Pim2 kinase stability and expression in transformed human hematopoietic cells.
Adam K et al. Biosci Rep. 2015 Oct 23. pii: BSR20150217. [Epub ahead of print].

Myeloma cells can corrupt senescent mesenchymal stromal cells and impair their anti-tumor activity.
Özcan S et al. Oncotarget. 2015 Oct 16. doi: 10.18632/oncotarget.5430. [Epub ahead of print].

Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients.
Calura E et al. Oncotarget. 2015 Oct 19. doi: 10.18632/oncotarget.6151. [Epub ahead of print].

Notch Increased Vitronection Adhesion Protects myeloma cells from drug induced Apoptosis.
Ding Y et al. Biochem Biophys Res Commun. 2015 Oct 19. pii: S0006-291X(15)30775-0. doi: 10.1016/j.bbrc.2015.10.076. [Epub ahead of print].

From CLL to Multiple Myeloma – Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration.
Lorenz J et al. Br J Haematol. 2015 Oct 22. doi: 10.1111/bjh.13825. [Epub ahead of print].

Molecular diagnostics of a single drug-resistant multiple myeloma case using targeted next-generation sequencing.
Ikeda H et al. Onco Targets Ther. 2015 Oct 5;8:2805-15. doi: 10.2147/OTT.S86515. eCollection 2015.

Halting prosurvival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA et al. Leukemia. 2015 Oct 21. doi: 10.1038/leu.2015.289. [Epub ahead of print].

The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediates Bortezomib Resistance in Multiple Myeloma.
Li B et al. J Biol Chem. 2015 Oct 19. pii: jbc.M115.664953. [Epub ahead of print].

The Aplidin analogs PM01215 and PM02781 inhibit angiogenesis in vitro and in vivo.
Borjan B et al. BMC Cancer. 2015 Oct 19;15:738. doi: 10.1186/s12885-015-1729-4.

Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.
Wang H et al. Oncotarget. 2015 Oct 14. doi: 10.18632/oncotarget.6116. [Epub ahead of print].

miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression.
Seckinger A et al. Oncotarget. 2015 Oct 12. doi: 10.18632/oncotarget.5381. [Epub ahead of print].

The effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma.
Zhou H et al. Exp Hematol. 2015 Oct 23. pii: S0301-472X(15)00695-5. doi: 10.1016/j.exphem.2015.10.004. [Epub ahead of print].

Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.
Burger MT et al. J Med Chem. 2015 Oct 27. [Epub ahead of print].

Clarithromycin Synergistically Enhances Thalidomide Cytotoxicity in Myeloma Cells.
Qiu XH et al. Acta Haematol. 2015 Oct 28;135(2):103-109. [Epub ahead of print.].

It’s Time to Take Clarithromycin Seriously in Multiple Myeloma.
Mark TM et al. Acta Haematol. 2015 Oct 28;135(2):101-102. [Epub ahead of print].

Increased NHC Cells in the Peritoneal Cavity of Plasmacytoma Susceptible BALB/c Mouse.
Sánchez-González B et al. Mediators Inflamm. 2015;2015:313140. doi: 10.1155/2015/313140. Epub 2015 Oct 4.

Merging colloidal nanoplasmonics and surface plasmon resonance spectroscopy for enhanced profiling ofmultiple myeloma-derived exosomes.
Di Noto G et al. Biosens Bioelectron. 2015 Oct 3;77:518-524. doi: 10.1016/j.bios.2015.09.061. [Epub ahead of print].

Prospective analysis of antigen-specific immunity, stem cell antigens and immune checkpoints in monoclonal gammopathy.
Dhodapkar MV et al. Blood. 2015 Oct 14. pii: blood-2015-03-632919. [Epub ahead of print].

A High Affinity hRpn2-Derived Peptide That Displaces Human Rpn13 from Proteasome in 293T Cells.
Lu X et al. PLoS One. 2015 Oct 14;10(10):e0140518. doi: 10.1371/journal.pone.0140518. eCollection 2015.

T cell exhaustion in multiple myeloma relapse after autotransplant: Optimal timing of immunotherapy.
Chung DJ et al. Cancer Immunol Res. 2015 Oct 13. pii: canimm.0055.2015. [Epub ahead of print].

Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors.
Hu H et al. Bioorg Med Chem Lett. 2015 Sep 30. pii: S0960-894X(15)30086-X. doi: 10.1016/j.bmcl.2015.09.052. [Epub ahead of print].

Recent advancements in molecular cytogenetics for hematological malignancies: identification of novel PVT1 fusion genes.
Taniwaki M et al. Rinsho Ketsueki. 2015 Oct;56(10):2056-65. doi: 10.11406/rinketsu.56.2056.

Inflammatory environment created by fibroblast aggregates induces growth arrest and phenotypic shift of humanmyeloma cells.
Szabova K et al. Neoplasma. 2015 Oct 13. doi: 10.4149/neo_2015_114. [Epub ahead of print].

Excess TGF-β mediates muscle weakness associated with bone metastases in mice.
Waning DL et al. Nat Med. 2015 Oct 12. doi: 10.1038/nm.3961. [Epub ahead of print].

Cancer-testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple Myeloma.
Lajmi N et al. Br J Haematol. 2015 Oct 12. doi: 10.1111/bjh.13762. [Epub ahead of print].

Identification of a p53-based portable degron based on the MDM2-p53 binding region.
Melvin AT et al. Analyst. 2015 Oct 12. [Epub ahead of print].

Compendium of FAM46C gene mutations in plasma cell dyscrasias.
Barbieri M et al. Br J Haematol. 2015 Oct 12. doi: 10.1111/bjh.13793. [Epub ahead of print].

Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD® immunomodulatory drug pomalidomide.
Das DS et al. Br J Haematol. 2015 Oct 12. doi: 10.1111/bjh.13780. [Epub ahead of print].

Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.
Vallabhapurapu SD et al. Nat Commun. 2015 Oct 12;6:8428. doi: 10.1038/ncomms9428.

Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation.
Liu Z et al. Oncotarget. 2015 Oct 7. doi: 10.18632/oncotarget.6020. [Epub ahead of print].

Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance.
He Y et al. Leuk Res. 2015 Sep 28. pii: S0145-2126(15)30390-8. doi: 10.1016/j.leukres.2015.09.019. [Epub ahead of print].

Idiotype-specific CD4+ T-cells eradicate disseminated myeloma.
Haabeth OA et al. Leukemia. 2015 Oct 9. doi: 10.1038/leu.2015.278. [Epub ahead of print].

Search for familial clustering of multiple myeloma with any cancer.
Frank C et al. Leukemia. 2015 Oct 9. doi: 10.1038/leu.2015.279. [Epub ahead of print].

Treatment with 5-Aza-2′-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing.
Klar AS et al. PLoS One. 2015 Oct 8;10(10):e0139221. doi: 10.1371/journal.pone.0139221. eCollection 2015.

CD4+ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma.
Zhang L et al. Oncotarget. 2015 Oct 3. doi: 10.18632/oncotarget.5506. [Epub ahead of print].

Multiple myeloma impairs bone marrow localization of effector Natural Killer cells by altering the chemokine microenvironment.
Ponzetta A et al. Cancer Res. 2015 Oct 5. pii: canres.1320.2015. [Epub ahead of print].

The novel mechanism of lenalidomide activity.
Fink EC et al.  Blood. 2015 Oct 5. pii: blood-2015-07-567958. [Epub ahead of print].

Triomics Analysis of Imatinib-Treated Myeloma Cells Connects Kinase Inhibition to RNA Processing and Decreased Lipid Biosynthesis.
Breitkopf SB et al. Anal Chem. 2015 Oct 12. [Epub ahead of print].

Cytogenetics in multiple myeloma patients progressing into extramedullary disease.
Besse L et al. Eur J Haematol. 2015 Oct 2. doi: 10.1111/ejh.12688. [Epub ahead of print].

Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC et al. Blood Cancer J. 2015 Oct 2;5:e354. doi: 10.1038/bcj.2015.66.

HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Canella A et al. Oncotarget. 2015 Oct 13;6(31):31134-50. doi: 10.18632/oncotarget.5290.

Tris DBA Palladium Overcomes Hypoxia Mediated Drug Resistance in Multiple Myeloma.
de la Puente P et al. Leuk Lymphoma. 2015 Sep 30:1-22. [Epub ahead of print].

Triptolide induces cell apoptosis by targeting H3K4me3 and downstream effector proteins in KM3 multiple myeloma cells.
Wen L et al. Curr Pharm Biotechnol. 2015 Sep 30. [Epub ahead of print].

Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.
Palma BD et al. Leukemia. 2015 Sep 30. doi: 10.1038/leu.2015.259. [Epub ahead of print].

DNA methylation of tumor suppressor protein-coding and non-coding genes in multiple myeloma.
Wong KY et al. Epigenomics. 2015 Sep 29. [Epub ahead of print].